Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03449836
Recruitment Status : Unknown
Verified February 2018 by Roberto Berni Canani, Federico II University.
Recruitment status was:  Not yet recruiting
First Posted : February 28, 2018
Last Update Posted : March 1, 2018
Sponsor:
Information provided by (Responsible Party):
Roberto Berni Canani, Federico II University

Tracking Information
First Submitted Date  ICMJE January 25, 2018
First Posted Date  ICMJE February 28, 2018
Last Update Posted Date March 1, 2018
Estimated Study Start Date  ICMJE March 1, 2018
Estimated Primary Completion Date September 30, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 28, 2018)
  • Total 5 Symptom Score (T5SS) from 0 to 15 [ Time Frame: after 20 days of treatment ]
    Symptoms evaluation was made by the Total 5 Symptoms Score (T5SS), which includes the symptoms of nasal discharge (rhinorrhea), nasal congestion, itchy nose, sneezing, and itchy eyes. All symptoms were graded from 0 (absent) to 3 (very troublesome),with total scores ranging from 0-15.
  • Pittsburgh Sleep Quality Index (PSQI) score [ Time Frame: after 20 days of treatment ]
    The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the 7 component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.Traditionally, the items from the PSQI have been summed to create a total score to measure overall sleep quality.
Original Primary Outcome Measures  ICMJE
 (submitted: February 22, 2018)
  • Paediatric Rhinoconjunctivitis Quality of Life Questionnaire [ Time Frame: after 20 days of treatment ]
    Total 5 Symptom Score (T5SS) from 0 to 15
  • Pittsburgh Sleep Quality Index (PSQI) score [ Time Frame: after 20 days of treatment ]
    Evaluation of sleep (score from 0 to >5)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2018)
Evaluation of nasal microbiota composition [ Time Frame: after 20 days of treatment ]
Evaluation of nasal microbiota composition with a nasal brushing and determination of phyla, class, order, family, genus
Original Secondary Outcome Measures  ICMJE
 (submitted: February 22, 2018)
  • Evaluation of nasal microbiota [ Time Frame: after 20 days of treatment ]
    Evaluation of nasal microbiota with a nasal brushing and fetermination of phyla, class, order, family, genus
  • Evaluation of nasal mucosa by validated scores [ Time Frame: after 20 days of treatment ]
    Evaluation of nasal mucosa with a nasal rhinofibroscopy (score from 0 to 10)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children
Official Title  ICMJE Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a With the Respiratory Epithelium in Children Affected by Allergic Rhinoconjunctivitis
Brief Summary Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure. This condition represents a global health problem that affects 5 to 20% of the population. As with all allergic diseases, its prevalence in pediatric age has increased over the last 30 years, as shown by the results of the international epidemiological study International Study of Asthma and Allergies in Childhood (ISAAC) which shows that the overall prevalence is 8.5 % in children aged 6-7 and 14.6% in children aged 13-14. In Italy, on average, the prevalence stands at 17.6% in the 6-7 year age range and 31.3% in the 13-14 age range, demonstrating a growing trend. The allergic rhinoconjunctivitis undiagnosed and / or not treated properly can negatively affect the school activities and in general the quality of life of children and their parents, as well as having important socio-economic repercussions in terms of medical expenses, school absences and days of work lost by parents. Furthermore, the lack of therapeutic intervention can lead to an increased risk of complications in the medium and long term. Recent advances in the understanding of the mechanisms underlying the inflammation of the airways have led to an improvement of the therapeutic strategies for the management of allergic rhinoconjunctivitis: the four cornerstones of the approach to this pathology promoted by the European Academy of Allergy and Clinical Immunology (EAACI) include allergen removal, patient education, pharmacotherapy and specific immunotherapy. However, there is discordant evidence to support their efficacy in reducing the symptomatology of allergic rhinoconjunctivitis, with the need to resort to the invasive surgical approach in several cases. Therefore, the use of probiotics, defined as "live micro-organisms which, when administered in adequate quantities, confer an advantage for the organism" can be useful. The mechanisms by which probiotics or their components, for example DNA, proteins and peptides, exert such beneficial effects concern the regulation of the immune system, the antagonist action against potentially pathogenic microorganisms and the quantitative and qualitative modulation of the intestinal microbiota. In fact, recent clinical studies have demonstrated the protective effect of infections of the high respiratory tract in adults and recurrent average otitis in pediatric age of the Streptococcus salivarius 24SMBc and Streptococcus oralis 89a strains administered through nasal spray. These well-characterized probiotics were safe, tolerated and able to positively modulate the composition of the respiratory epithelial microbiota and the function of the immune system.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Allergy
Intervention  ICMJE
  • Combination Product: Streptococcus salivarius 24SMBc + Strept. oralis 89a
    nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
  • Combination Product: fluticasone + mometasone
    nasal spray based on fluticasone + mometasone
  • Other: placebo
    nasal spray based on isotonic solution
Study Arms  ICMJE
  • Experimental: Streptococcus salivarius 24SMBc + Strept.oralis 89a
    spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
    Intervention: Combination Product: Streptococcus salivarius 24SMBc + Strept. oralis 89a
  • Active Comparator: fluticasone + mometasone
    spray with fluticasone and mometasone
    Intervention: Combination Product: fluticasone + mometasone
  • Placebo Comparator: placebo
    spray with isotonic solution
    Intervention: Other: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: February 22, 2018)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2018
Estimated Primary Completion Date September 30, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • children aged 6-12 months with allergic rhinoconjunctivitis

Exclusion Criteria:

  • concomitant presence of chronic pathologies,
  • malformations of the respiratory tract and facial cranium,
  • tumors,
  • neurological diseases,
  • metabolic pathologies,
  • cystic fibrosis,
  • immunodeficiencies,
  • history of epistaxis,
  • alteration of coagulation factors,
  • history of apnea,
  • ciliary dyskinesia,
  • treatment with topical drugs nasal steroids and / or oral anti-histaminics or antibiotic treatment in the 3 months prior to enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Years to 12 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03449836
Other Study ID Numbers  ICMJE 274/17
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Roberto Berni Canani, Federico II University
Study Sponsor  ICMJE Federico II University
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Federico II University
Verification Date February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP